Novartis 4Q Revenues: $13.2 billion (+15%) 4Q Earnings: $2.8 billion (-67%) FY Revenues: $50.3 billion (+11%) FY Earnings: $11.9 billion (-24%) Comments: Sales growth in the quarter was mainly driven by Entresto with $2.2 billion in sales, up 33%, Kesimpta sales of $950 million, up 48%, Kisqali sales of $902 million, up 48%, Cosentyx sales of $1.6 billion, up 22%, and Leqvio sales of $223 million, up 81%, partly offset by declines mainly for Lucentis, with sales down 30% to $210 m...